Natco Pharma Limited Total Liabilities
Natco Pharma Limited total liabilities. Based on the latest financial reports, Natco Pharma Limited (NATCOPHARM) has total liabilities worth Rs17.76 Billion INR (≈ $192.06 Million USD) as of September 2025. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. Check asset resilience ratio of Natco Pharma Limited to evaluate the company's liquid asset resilience ratio.
Total Liabilities of Natco Pharma Limited (2005–2025)
Total liabilities of Natco Pharma Limited from 2005 to 2025. This chart illustrates how Natco Pharma Limited's total liabilities have evolved over time, based on quarterly financial data. Explore Natco Pharma Limited long-term investment intensity to see how much of total assets are deployed in long-term investments.
Natco Pharma Limited Competitors by Total Liabilities
The table below lists competitors of Natco Pharma Limited ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Ruentex Engineering & Construction Co Ltd
TW:2597
|
Taiwan | NT$15.91 Billion |
|
Guilin Sanjin Pharmaceutical Co Ltd
SHE:002275
|
China | CN¥1.05 Billion |
|
Odontoprev S.A
SA:ODPV3
|
Brazil | R$958.26 Million |
|
Helios Technologies Inc
NYSE:HLIO
|
USA | $567.70 Million |
|
Mesoblast Limited
F:LWB
|
Germany | €207.62 Million |
|
AG Anadolu Group Holding
IS:AGHOL
|
Turkey | TL348.37 Billion |
|
Thai Union Group PCL
BK:TU
|
Thailand | ฿107.93 Billion |
|
Thai Union Group Public Company Limited
BK:TU-R
|
Thailand | ฿108.00 Billion |
Liability Composition Analysis (2005–2025)
This chart breaks down Natco Pharma Limited's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. For the complete balance sheet picture, see Natco Pharma Limited (NATCOPHARM) total assets.
Liquidity & Leverage Metrics
Natco Pharma Limited Total Liabilities Ratios Explained
Natco Pharma Limited total liabilities ratios compare its liabilities with its current assets, cash and shareholder equity.
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 4.10 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | 1.58 | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 0.21 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.17 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Natco Pharma Limited's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Natco Pharma Limited (2005–2025)
The table below shows the annual total liabilities of Natco Pharma Limited from 2005 to 2025.
| Year | Total Liabilities | Change |
|---|---|---|
| 2025-03-31 | Rs10.19 Billion ≈ $110.15 Million |
-3.29% |
| 2024-03-31 | Rs10.53 Billion ≈ $113.90 Million |
-130.26% |
| 2023-03-31 | Rs-34.80 Billion ≈ $-376.35 Million |
-511.59% |
| 2022-03-31 | Rs8.46 Billion ≈ $91.44 Million |
+26.48% |
| 2021-03-31 | Rs6.68 Billion ≈ $72.30 Million |
-16.76% |
| 2020-03-31 | Rs8.03 Billion ≈ $86.85 Million |
-1.11% |
| 2019-03-31 | Rs8.12 Billion ≈ $87.83 Million |
+27.07% |
| 2018-03-31 | Rs6.39 Billion ≈ $69.12 Million |
-3.78% |
| 2017-03-31 | Rs6.64 Billion ≈ $71.83 Million |
+27.59% |
| 2016-03-31 | Rs5.21 Billion ≈ $56.30 Million |
-2.33% |
| 2015-03-31 | Rs5.33 Billion ≈ $57.64 Million |
+15.12% |
| 2014-03-31 | Rs4.63 Billion ≈ $50.07 Million |
-13.68% |
| 2013-03-31 | Rs5.36 Billion ≈ $58.00 Million |
+24.53% |
| 2012-03-31 | Rs4.31 Billion ≈ $46.58 Million |
+21.72% |
| 2011-03-31 | Rs3.54 Billion ≈ $38.27 Million |
+47.28% |
| 2010-03-31 | Rs2.40 Billion ≈ $25.98 Million |
-4.08% |
| 2009-03-31 | Rs2.50 Billion ≈ $27.09 Million |
+28.90% |
| 2008-03-31 | Rs1.94 Billion ≈ $21.01 Million |
+18.65% |
| 2007-03-31 | Rs1.64 Billion ≈ $17.71 Million |
+6.27% |
| 2006-03-31 | Rs1.54 Billion ≈ $16.67 Million |
-11.31% |
| 2005-03-31 | Rs1.74 Billion ≈ $18.79 Million |
-- |
About Natco Pharma Limited
NATCO Pharma Limited, a pharmaceutical company, engages in the research and development, manufacturing, and marketing of finished dosage formulations, active pharmaceutical ingredients (APIs), and intermediates in India, the United States, and internationally. The company offers formulations in various therapeutic areas, including cancers of blood, liver, kidney, lung, brain, breast, and ovary; a… Read more